Table 1 Demographics and clinicopathological features characterizing the CRS cohort under investigation.

From: Urine peptidome analysis in cardiorenal syndrome reflects molecular processes

 

Control

CRS

Number

356

353

Sex, male (%)

67

68

Age (years)

70 ± 7

72 ± 8

BMI

26.75 ± 4.00

29.19 ± 5.29*

Smoking status (yes, %)

9.5

5.3*

eGFR (CKD-EPI) (ml/min/1.73 m2)

79.2 ± 18.8

43.1 ± 11.5*

CKD Stage 5 (%)

N/A

1

CKD Stage 4 (%)

N/A

14

CKD Stage 3 (%)

N/A

85

NT-proBNP (pg/mL)

195.16 ± 195.49

1587.48 ± 2111.07*

Serum creatinine (μmol/L)

79.20 ± 12.81

138.04 ± 47.15*

Ejection fraction

N/A

40.10 ± 11.92

Systolic BP (mmHg)

141.66 ± 18.13

126.91 ± 24.57*

Diastolic BP (mmHg)

79.75 ± 8.99

67.44 ± 13.16*

Diagnosis (%) HF/HFrEF/HFpEF/HFmrEF

N/A

15/60/20/5

  1. Differences between controls and CRS have been evaluated by the Mann–Whitney U test (for continuous variables) or Chi-Square test (for categorical variables) and are marked with * when P < 0.05. Data are presented as mean ± standard deviation (s.d.) or number (%).
  2. BMI: body mass index; eGFR: estimated glomerular filtration rate; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CKD Stage 5: 0–15 ml/min/1.73 m2; CKD Stage 4: 15–29 ml/min/1.73 m2; CKD Stage 3: 30–60 ml/min/1.73 m2; NT-proBNP: N-terminal pro b-type natriuretic peptide; BP: blood pressure; HF: heart failure; HFrEF: heart failure with reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; N/A: not applicable.
Back to article page